π©Έ Liquid Biopsy - Feb 2026
β’ Urine biopsies detect minimal residual disease in bladder cancer
β’ Pan-cancer analysis identifies 14,202 methylation regions for cancer detection
β’ Multi-omics integration boosts sensitivity in the PROMISE study
β’ M-PACT classifies pediatric CNS tumors from low-input cfDNA
β’ High ctDNA tumor fraction linked to worse survival in germ cell tumors
β’ Hyaluronan mediates CTC clustering in triple-negative breast cancer
AI Liquid Biopsy Detects Early Liver Fibrosis and Cirrhosis Before Symptoms
π° Original title: AI blood test finds silent liver disease years before symptoms
π€ IA: It's not clickbait β
π₯ Usuarios: It's not clickbait β
View full AI summary: https://killbait.com/en/ai-liquid-biopsy-detects-early-liver-fibrosis-and-cirrhosis-before-symptoms/?redirpost=bde6c4e8-f997-4994-b08c-67cf9b56f7d3
π§ͺ Liquid Biopsy β Jan 2026
β’ Post-treatment ctDNA predicts recurrence across multiple cancers
β’ Baseline mutation status refines prognosis in advanced disease
β’ CTCs and EV-derived signals guide therapy response
Extracellular Vesicles - Dec 2025 π§ͺ
β’ Vesicle signaling linked to cancer progression and therapy resistance
β’ Exosome liquid biopsies show high accuracy for early cancer detection
β’ EVs mediate mitochondrial quality control and tissue protection
β’ Hybrid vesicles enhance oral antibiotic absorption and mitigate gut dysbiosis
β’ Engineered vesicles improve drug delivery
Neuro-oncology β Dec 2025 π§ π§¬
Brain mets, gliomas & immunotherapy moved fast last month:
β’ Liquid biopsy hits 98% accuracy from blood
β’ CNS tumor classes expand to 184 types
β’ New immune strategies boost antitumor response
Full summary: http://pir.sh/z0odQpM1LO
I hope everyone's watching #CancerDetectives on Channel 4!
My team has sweated over various aspects of this. It's a big passion project, my colleague's second baby, and hopefully will help more people understand what it means to do #CancerResearch today, and indeed what it means to have cancer now, compared to some decades ago.
#channel4 #cancer #cancerVaccines #BrainTumours #LiquidBiopsy #cancerOfUnknownPrimary #LungCancer #P53 #liFraumeni #5GTrial #MILITrial #DETECTION2Trial #CancerResearchUK
π Could buffer design revolutionize how we detect circulating tumor cells (CTCs) in cancer patients?
π Design of buffer property for the new enrichment method of circulating tumor cell based on immunomagnetic-negative separation. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2024.11.033
π CSBJ Nanoscience & Advanced Materials: https://csbj.org/nano
#CancerResearch #LiquidBiopsy #Oncology #Immunotherapy #PrecisionMedicine #CancerDiagnostics #Biomarkers #CancerDetection
Can ex-smokers cut down their lung cancer risk? Oncologist shares 5 tips to know
Quitting smoking is a difficult process, especially for the ones who are addicted. However, when you quit smoking,β¦
#NewsBeep #News #Headlines #exsmokers #healthylifestyle #Latvia #liquidbiopsy #LungCancer #LV #quitsmoking #tobacco-relatedharm
https://www.newsbeep.com/142467/
π 'Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer' - a DrugRxiv #Preprint on #ScienceOpen:
β‘οΈ https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGARXIV.PR000030.v1
#REPO4EU #DrugRepurposing #AnaplasticThyroidCancer #ExtracellularVesicles #Vandetanib #LiquidBiopsy
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d660062e280"> <b>Background: </b>Anaplastic thyroid cancer (ATC) is an aggressive and rare disease. Rapid metastasis and limited treatments call for additional therapeutic options, including drug repurposing. The early spreading of ATC highlights the importance of rapid therapy success assessment, which could be achieved by measurement of extracellular vesicle (EV)-associated cell-free RNA in liquid biopsy samples. Recent studies have discovered the potential of the receptor tyrosine kinase inhibitor vandetanib for ATC treatment <i>in vitro</i> and <i>in vivo</i>. Given the rarity of ATC patients receiving off-label vandetanib treatment, acquiring patient samples for clinical studies is a prolonged process, and pre-clinical investigations are needed to elucidate the effects of vandetanib on ATC cells. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d660062e291"> <b>Objective:</b> Here, we present an <i>in vitro</i> study addressing holistic transcriptional and proteomic changes induced in the ATC cell line Cal62 by three doses of vandetanib and quantified by high-throughput methods. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d660062e299"> <b>Methods:</b> By comparing the transcriptional and proteomic data sets and applying dimensional reduction models such as sparse partial least-squares discriminant analysis, we refined a set of 21 biomarker candidates. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d660062e304"> <b>Results:</b> Out of these, we report a final signature of eight transcriptional biomarkers, validated in cellular and cell-free RNA by RT-qPCR and verified for biological significance and discriminatory power by pathway over-representation analysis and partial least-squares regression. This transcriptional biomarker signature can distinguish vandetanib treatment from control in cell-free RNA isolated from Cal62 EVs and can be measured reliably, easily, and quickly using RT-qPCR. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d660062e309"> <b>Conclusions:</b> Our findings may serve as a basis for future clinical trials with liquid biopsy samples from ATC patients undergoing off-label vandetanib treatment. </p>
Summarized Science
KillBait
Noodlemaz
CSBJ
News Beep
ScienceOpen
Yonhap Infomax News